Notice of Results

RNS Number : 7872N

EpiStem Holdings plc

24 February 2009

 

Notification of Interim Results (Half Year Results)

Epistem (AIM: EHP), the rapidly growing biotechnology company with adult epithelial stem cell expertise in oncology, gastrointestinal and dermatological diseases will announce its interim results for the six months ended 31 December 2008 on Wednesday, 11 March 2009.  

An analysts' meeting will be held at 9.30am on Wednesday, 11 March 2009 at the offices of De Facto 
Communications, 330 High Holborn, London WC1V 7QD.

For further information, please contact: 

Epistem 

Matthew Walls CEO                                                          [phone]
John Rylands CFO

Piper Jaffray Ltd. 

Neil Mackison / James Steel                                              [phone]
Corporate Broking: Jamie Adams    

De Facto Communications 

Mike Wort / Anna Dunphy                                                  [phone]

Notes to Editors

Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.

 

END

 

 

NORMGGZZMDLGLZM